Electromed, Inc. (ELMD) AI Stock Analysis

Electromed, Inc. specializes in the development, manufacturing, marketing, and global distribution of airway clearance therapy systems utilizing high frequency chest wall oscillation (HFCWO) technology. Founded in 1992 and based in New Prague, Minnesota, the company provides pulmonary solutions for patients with conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. Its flagship offering is the SmartVest airway clearance system, which includes the SmartVest SQL System and SmartVest Connect wireless technology for personalized therapy management. Electromed primarily serves home health care providers and institutional markets, delivering respiratory care solutions to healthcare professionals and patients worldwide.

Electromed grew annual revenue from $41.7M in FY2022 to $73.8M in FY2026, achieving a 5-year revenue CAGR of 15.6%. Gross margin expanded from 75.5% in FY2022 to 78.5% in FY2026, while operating margin increased from 7.1% to 18.8% over the same span. Net income rose from $2.3M in FY2022 to $11.3M in FY2026, bringing EPS to $1.31. For the latest quarter ended June 30, 2026, quarterly revenue growth was 11.6% year-over-year, while quarterly earnings grew 49.0% year-over-year. Trailing twelve-month operating margin reached 19.7% on a profit margin of 15.3%.

As of June 30, 2026, Electromed held $20.4M in cash and short-term investments against total debt of $133,000, resulting in net cash of $20.3M. Shareholders' equity was $54.0M, and the current ratio stood at 4.69 with a debt-to-equity ratio of 0.00. In FY2026, the company produced $9.7M in operating cash flow and $8.4M in free cash flow. Electromed used its cash flow for $1.3M in capital expenditures and $3.9M in share buybacks.

At $27.42 per share, Electromed trades at a trailing P/E of 21.1x, below the 24.6x median of its US-listed Healthcare peers. Its forward P/E of 20.2x and EV/EBITDA of 14.1x both trade above the US-listed Healthcare medians of 17.3x and 12.0x, respectively. The company's price-to-sales ratio is 3.1x compared to the peer median of 4.1x. Over the past year, the stock returned 12.8%, trailing the S&P 500 (SPY) return of 16.8%, but its 5-year return of 149.5% outperformed the index return of 83.0%.

Wall Street analysts currently assign Electromed 3 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $48.50, which sits 76.9% above the last close of $27.42. For the fiscal year ending June 30, 2027, consensus estimates project revenue of $83.2M and EPS of $1.46, representing 11.9% earnings growth. Electromed has beaten EPS estimates in each of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Electromed, Inc. (ELMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELMD income statement, ELMD balance sheet, ELMD key metrics, ELMD analyst forecast, ELMD chart. See the ELMD stock overview for the latest quote and news.